With over three decades of dedicated experience in influenza virus research, I have cultivated a comprehensive expertise encompassing molecular virology, reverse genetics, and host range studies. My research program, distinguished by its innovative combination of reverse genetics and diverse animal models, has yielded significant advancements in our understanding of influenza pathogenesis and transmission dynamics across avian and mammalian species. In response to the SARS-CoV-2 pandemic, my research group expanded its scope to encompass in vitro, and in vivo studies focused on unraveling the complexities of SARS-CoV-2 pathogenesis. This multifaceted approach has allowed for the exploration of intricate host-pathogen interactions, shedding light on the mechanisms underlying influenza virus infection and spread. My laboratory's pioneering work in developing attenuation strategies for influenza A and B viruses has led to the creation of live attenuated vaccines exhibiting exceptional safety and efficacy in pre-clinical trials. This breakthrough represents a significant step forward in the development of next-generation influenza vaccines that can effectively prevent disease transmission and reduce the severity of illness. One of these promising strategies is currently under a preliminary licensing agreement for potential application in swine and other animal species, underscoring the translational potential of our research findings. Beyond vaccine development, my team has also made substantial contributions to the field of diagnostics. Our successful development of a monoclonal antibody, now licensed to Zoetis and incorporated into the FluDetect rapid avian influenza diagnostic kit, exemplifies our commitment to developing innovative tools for the rapid and accurate detection of influenza viruses. This point-of-care strip test represents a significant advancement in field diagnostics, enabling timely interventions and control measures for avian influenza outbreaks. My leadership experience in large-scale research initiatives, including my role as Program Director of the USDA-NIFA-funded "Prevention and Control of Avian Influenza in the US" project, demonstrates my ability to effectively manage complex multi-institutional projects and foster collaborations among diverse research teams. This experience has equipped me with the skills necessary to navigate the intricacies of large-scale research endeavors, ensuring efficient coordination, communication, and resource allocation. Furthermore, my laboratory's active participation in NIAID-NIH Centers of Excellence for Influenza Research, both past (Center for Research on Influenza Pathogenesis; CRIP-CEIRS) and present (Center for Research on Influenza Pathogenesis and Transmission; CRIPT-CEIRR), highlights our ongoing commitment to collaborative research and knowledge exchange within the broader scientific community. These collaborations have fostered the development of novel research approaches and facilitated the sharing of valuable insights and resources, ultimately accelerating progress in the fight against influenza.
- New approaches to longstanding diseases: African swine fever, Avian influenza. - Improving our understanding recombination, immunology and vaccine targets. - How do we define and measure "impact" in the absence of sterile immunity – DIVA vaccines? - Innovative delivery systems including microneedle patches, intranasal, and oral platforms for mass vaccination - Multivalent vaccine development: navigating formulation, stability, and immune interference across species